Compare Johnson & Johnson (JNJ) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs McCormick & Company, Incorporated — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while McCormick & Company, Incorporated trades at $44.81 (market cap $12.39B). The key difference: Johnson & Johnson is far larger — about 49.9× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays the higher dividend (4.18%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and McCormick & Company, Incorporated for 67 Days on average.
| JNJ | MKC | |
|---|---|---|
Market Cap | $618.09B | $12.39B |
Volume | 6,050,983 | 6,140,872 |
Sector | Health | Consumer Staples |
52-Week High | $278.43 | $71.65 |
52-Week Low | $186.00 | $44.14 |
Typical Hold Time | 129 Days | 67 Days |
Enterprise Value | $646.37B | $17.07B |
Dividend Yield | 2.09% | 4.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
McCormick & Company (MKC) trades at $45.94, showing modest daily gains of 1.52%. The stock presents a mixed technical picture with bearish moving averages but neutral oscillators, while fundamentally it maintains strong profitability with 19.39% net income margin and attractive valuation at 8.31 P/E. Recent Q3 2026 earnings beat expectations with $0.86 EPS, driven by 17% sales growth and margin expansion from the Mexico acquisition.
MKC offers value with discounted valuation and dividend yield, but faces technical headwinds and competitive pressures. The consensus price target of $53.50 suggests 16% upside potential, though analyst sentiment remains cautious with 60% hold ratings. Key risks include integration challenges from acquisitions and consumer spending sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
